pharmacies in egypt, revitalife drip, bhrt, biohormone replacement therapy, iv drip, iv therapy, egypt pharmacy, pharmaceutical companies, compounding pharmacy egypt, compounding pharmacy, erectile dysfunction, find a compounding pharmacy, hair care, multi vitamins, iv infusions, pharmacy egypt, egypt pharmacy, pharmacy near me, revitalife clinic, pharmacy, revitalife pharmacy
Ophthalmic Preparations

Revitalife Ophthalmic Preparations (eye preparations) are sterile and liquid preparations that may contain one or more active pharmaceutical ingredient(s) intended for application to the conjunctiva, the conjunctival sac or the eyelids. The following are subclassification of our ophthalmic preparation:

  • Intravitreal solution for injection
    Intravitreal solution for injection of substances dissolved in a vehicle solution is a common tool used to assess retinal function. Intravitreal Injections are now standard treatment for various ocular conditions such as age-related macular degeneration, diabetic retinopathy and retinal vein occlusions.
  • Eye Drops
    Principally absorbed through the cornea and absorption through conjunctival mucosa also occurs, giving rise to systemic effects.
  • Eye Ointments
    Ointments allow a prolonged contact time; therefore, less frequent applications are required (good for night use).


Clarity- Revitalife Ophthalmic Solutions is free from foreign particles, which is generally accomplished by filtration. The filtration achieved clarity of the solution.

Tonicity– Lacrimal fluid has an isotonicity value equivalent to that of a 0.9% sodium chloride solution. However, the eye can tolerate a value as low as 0.6% and as high as 1.8% sodium chloride equivalency. Several of our ophthalmic solutions will be hypertonic by the nature of the high concentration required of the drug substance. Some will be hypotonic and will require the addition of a substance to attain the proper tonicity range. Sodium chloride, boric acid, and dextrose are commonly used. Three hundred mOsm/L is ideal with 200-600 mOsm/L acceptable which is the range of our ophthalmic products.

pH and Buffering– Revitalife ophthalmic solutions are buffered at the pH of maximum stability for the drug(s) they contain. The buffers are included to minimize any change in pH during the storage life of the drug.

Sterility– Revitalife ophthalmic solutions are sterile. Sterility is achieved through sterile filtration using a sterile membrane filter of 0.45 or 0.2 micron pore size and filtering into a sterile container.

Preservation– Revitalife ophthalmic solutions are prepared in multiple use containers. The selected preservative is compatible with the active drug as well as all the other excipients in the product.


a. Intravitreal injections:

  • Bevacizumab
  • Triamcinolone acetonide (Kenalog)
  •  Ganciclovir
  •  Foscarnet
  •  Cidofovir
  •  Fomvirsen
  •  Methotrexate
  • Vancomycin
  • Ceftazidime
  • Amikacin
  • Amphotericin B
  • Voriconazole
  • Dexamethasone
  • Voriconazole intrastromal injection

b. Eye drops:

  • Vancomycin ED
  • Tacrolimus ED
  • Cefazolin ED
  • Cyclosporine ED
  • Fluconazole ED
  • Methyl prednisolone ED
  • Mitomycin ED
  • Fortified tobramycin ED
  • Gentamicin ED
  • Amikacin
  • Linezolid ED
  • Colistin ED
  • Imepenim-cilastin ED
  • Amphotericin ED
  • Voriconazole ED

c. Eye ointment

  • Tacrolimus EO
  • Amphotericin B EO

Packaging of Revitalife ophthalmic solutions is appropriately done in sterile dropper bottles or individual doses can be placed in sterile syringes, without needles.

Revitalife ophthalmic preparations should be stored at either room or refrigerated temperatures and should not be frozen.

Revitalife Ophthalmic Solution beyond used date is not later than 7 days under refrigeration and 4 days in room temperature, when stored at refrigerated temperatures, for products prepared from ingredients in solid form.


  • External Disease and Cornea. American Academy of Ophthalmology 1999-2000.
  • Jain R, Murthy SI, Motukupally S. Clinical outcomes of corneal graft infections caused by Multi – drug resistant Pseudomonas aeruginosa keratitis. Cornea 2014;33: 22-26.
  • Prabhasawat P, Chotikavanich S, Leelaporn A. Sterility of non preservative eye drops. J Med Assoc Thai. 2005;88:S6-10.
  • Karampatakis V, Papanicolaou T, Giannousis M, Goulas A et al. Stability and antibacterial potency of ceftazidime and vancomycin eye drops reconstituted in BSS against Pseudomonas aeruginosa and Staphyloccoccus aureus. Acta Ophthalmologica 2009; 87(5):555-558.
  •  Shao Y, Yao Y, Chong Gang P, Tan Y et al. Therapeutic efficacy of intracameral amphotericin B injection for 60 patients with keratomycosis. Int J ophthalmol 2010;3(3):257- 260.
  • Prakash G, Sharma N, Goel M, Titiyal JS, Vajpayee RB. Evaluation of intrastromal injection of voriconazole as a therapeutic adjunctive for the management of deep recalcitrant fungal keratitis. Am J Ophthalmol 2008; 146: 56-59.
  •  Dupuis A, Tournier A, Moal GL, Venisse N. Preparation and stability of voriconazole eye drop solution. Antimicrobial agents and chemotherapy; Feb 2009: 798-799.
  • U.S. Pharmacopeia 23/National Formulary 18, Rockville MD, U.S. Pharmacopeial Convention, Inc., 1995
  • Ansel HC, Popovich NG, Allen Jr LV. Pharmaceutical Dosage Forms and Drug Delivery Systems, Baltimore MD, Williams & Wilkins, 1995.
  • Wade A, Weller PJ. Handbook of Pharmaceutical Excipients, 2nd Ed, Washington DC, American Pharmaceutical Association, 1994.
  •  Reynolds LA, Closson RG, Extemporaneous Ophthalmic Preparations, Vancouver WA, Applied Therapeutics, Inc., 1993. 6. Anon. Ophthalmic Drug Facts 1998. St Louis MO, Facts and Comparisons-A Wolters Kluwer Commpany, 1998.
  • Baner GS, Rhodes CT. Modern Pharmaceutics, 3rd Ed., New York, Marcel Dekker, Inc., 1995.
  • Ranade VV, Hollinger MA. Drug Delivery Systems. Boca Raton, CRC Press, 1996.

Our Location

Quote of the Day